News
Biovica provides updates on FDA application
Uppsala, Sweden, March 10, 2020. Biovica, active in cancer diagnostics, today announced that the company intends to submit an FDA application for market approval of DiviTum in the third quarter of 2020 and not as previously announced in mid-2020.
Clinical Cancer Research publishes results supporting DiviTum as a technology for early evaluation of metastatic breast cancer treatment
Biovica, active in cancer diagnostics, today announced that the scientific journal Clinical Cancer Research has published data from the TREnd study, demonstrating the benefits of using DiviTum® when evaluating palbociclib treatment outcome in women with metastatic breast cancer.
Biovica strengthens management team
Biovica, active in cancer diagnostics, today announced that Henrik Winther was appointed SVP Business Development and will be part of the management team. He most recently comes from the role of SVP Precision Diagnostics at Immunovia.
Q2 Interim report: Work with the FDA application progressing as planned
“The results from two additional studies with DiviTum® will be presented at San Antonio Breast Cancer Symposium, the world’s largest scientific conference on breast cancer”. – Anders Rylander, CEO of Biovica
Biovica’s DiviTum – Strong prognostic marker in operable breast cancer
Uppsala, Sweden, November 20, 2019. Biovica, active in cancer biomarkers, today announced clinical data that demonstrate DiviTum as a strong prognostic marker in operable breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium, SABCS, December 10-14, 2019, the world ́s largest scientific congress focusing on breast cancer.
Biovica’s DiviTum validated as a dynamic biomarker in metastatic breast cancer in collaboration with Institut Curie, Paris
Uppsala, Sweden, November 20, 2019. Biovica, active in cancer biomarkers, today announced that clinical data – demonstrating that DiviTum can be used as a dynamic, non-invasive biomarker for metastatic breast cancer patients treated with endocrine therapy and palbociclib – will be presented at the San Antonio Breast Cancer Symposium, December 10-14, 2019, the world ́s largest scientific congress focusing on breast cancer.
Biovica strengthens with new R&D Director
Uppsala, November 15, 2019. Biovica, active in cancer diagnostics, today announced that Otti Bengtsson Gref has been appointed new R&D Director and will be part of the management team. She most recently comes from the role as R&D Director at Cavidi.
Biovica ISO 13485:2016 certificate renewal
Uppsala, Sweden, October 25, 2019. Biovica, active in cancer diagnostics, announced today that the company has renewed their ISO 13485:2016 certificate for three years following an extensive renewal audit with the company’s accreditation body. The certificate covers the development, manufacturing and sale of DiviTum®.
Biovica will present at the Biomarkers & Precision Medicine Congress in San Diego
The 4th Annual Biomarkers & Precision Medicine Congress will be arranged October 8-9 in San Diego, USA. With increased focus on precision medicine follows a need to translate scientific progress into patient benefits through personalized healthcare. The focus of the Biomarker Congress is the discovery and clinical development of biomarkers and Biovica has been invited to present DiviTum®. The congress includes presentations, case studies and panel discussions with participants from global pharmaceutical and biotech companies, as well as academic institutions.
Biovica invites to telephone conference/audiocast
Uppsala, Sweden, September 18, 2019. Biovica invites investors, analysts and the media to a presentation where Anders Rylander, CEO, and Mattias Bergqvist, Clinical Development Director, comments on today’s announcement. The presentation will be held on 19 September 2019 at 10:00 CET and can be followed via telephone conference or audiocast.